Erratum to: 36th International Symposium on Intensive Care and Emergency Medicine

[This corrects the article DOI: 10.1186/s13054-016-1208-6.]

Lichens as biomonitors at indoor environments of primary schools

Radiation, Radionuclides and ReactorsApplied Science

Burn wood influence on outdoor air quality in a small village: Foros de Arrao, Portugal

Radiation, Radionulcides and ReactorsApplied Science

Understanding the effect of the high hydrophobicity of the laser-prepared Ti/SnO₂-Sb-La₂O₃anode on its electrocatalytic properties

SnO2-Based materials have attracted much attention in the electrochemical oxidation field due to their high electrocatalytic activity. However, efforts are still required to improve their physical and electrochemical properties. Here we employed a CO2 laser thermal process, as a substitute to conventional furnace heating, for the synthesis of two SnO2-based anodes-Ti/SnO2-Sb2O5 and Ti/SnO2-Sb-La2O3. Compared with anodes made using conventional heating, the laser-prepared anodes show a more compact surface and a change from hydrophilic to super-hydrophobic wetting properties. Energy-dispersive X-ray spectroscopy and X-ray diffraction data reveal the uniform distribution of Sn, Sb, and La, as well as the formation of the desired oxides, respectively. The oxidation state and chemical composition were confirmed by X-ray photoelectron spectroscopy. Notably, the laser-prepared anodes exhibit a positive shift in the oxygen evolution overpotential, especially for the Ti/SnO2-Sb-La2O3 anode, and a 2-fold reduction in the charge transfer resistance. The electrochemical degradation of 4-nitrophenol (4-NP) was investigated in aqueous solutions by UV-Vis spectra employing all anodes produced. The results showed that laser-prepared Ti/SnO2-Sb-La2O3 displays the highest degradation efficiency at the lowest energy consumption. Also, a mechanism for the 4-NP oxidation at the SnO2-based anodes under the current working conditions is proposed. Finally, the notable reduction in processing time and energy spent using laser heating makes it a feasible alternative to produce SnO2-based anodes. Their improved properties enhance the potential of these anodes to be applied in the electrochemical treatment of polluted waters.Large Scale Energy Storag

InP Nanowire Biosensor with Tailored Biofunctionalization: Ultrasensitive and Highly Selective Disease Biomarker Detection

Electrically active field-effect transistors (FET) based biosensors are of paramount importance in life science applications, as they offer direct, fast, and highly sensitive label-free detection capabilities of several biomolecules of specific interest. In this work, we report a detailed investigation on surface functionalization and covalent immobilization of biomarkers using biocompatible ethanolamine and poly(ethylene glycol) derivate coatings, as compared to the conventional approaches using silica monoliths, in order to substantially increase both the sensitivity and molecular selectivity of nanowire-based FET biosensor platforms. Quantitative fluorescence, atomic and Kelvin probe force microscopy allowed detailed investigation of the homogeneity and density of immobilized biomarkers on different biofunctionalized surfaces. Significantly enhanced binding specificity, biomarker density, and target biomolecule capture efficiency were thus achieved for DNA as well as for proteins from pathogens. This optimized functionalization methodology was applied to InP nanowires that due to their low surface recombination rates were used as new active transducers for biosensors. The developed devices provide ultrahigh label-free detection sensitivities ∼1 fM for specific DNA sequences, measured via the net change in device electrical resistance. Similar levels of ultrasensitive detection of ∼6 fM were achieved for a Chagas Disease protein marker (IBMP8-1). The developed InP nanowire biosensor provides thus a qualified tool for detection of the chronic infection stage of this disease, leading to improved diagnosis and control of spread. These methodological developments are expected to substantially enhance the chemical robustness, diagnostic reliability, detection sensitivity, and biomarker selectivity for current and future biosensing devices.Accepted Author ManuscriptBN/Nynke Dekker La

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics